Medication-assisted treatment (MAT) combines FDA-approved medications with counseling and behavioral therapies to treat substance use disorders, primarily opioid and alcohol addiction. It’s considered a “whole-patient” approach, meaning the medication addresses the physical side of addiction while therapy targets the psychological and behavioral patterns that drive it. MAT is one of the most effective tools available for opioid use disorder in particular, with research showing it reduces relapse, lowers overdose risk, and helps people stay in treatment long enough to build lasting recovery.
How MAT Works
Addiction changes brain chemistry in ways that make willpower alone extremely difficult to sustain. The medications used in MAT work by stabilizing those brain changes, reducing cravings, or blocking the rewarding effects of drugs and alcohol. This gives people enough relief from the physical pull of addiction to engage meaningfully in the counseling and skill-building that support long-term recovery.
Without the medication component, outcomes are significantly worse. One study found that 60% of participants stayed opioid-free while on medication, compared to only 20% of those receiving no pharmacological treatment. Multiple studies have concluded that psychosocial treatment alone, without medication, is ineffective at managing opioid dependence long-term. As one researcher put it, detoxification alone will not prevent relapse when someone returns to the environment that encouraged their use in the first place.
Medications for Opioid Use Disorder
Three medications are FDA-approved for treating opioid addiction. Each works differently, and which one a person uses depends on their history, preferences, and medical needs.
Buprenorphine is the most widely prescribed. It partially activates the same brain receptors that opioids target, which eases cravings and withdrawal symptoms without producing the intense high of full opioids. It comes in several forms: daily dissolving tablets or films placed under the tongue, and monthly injections for people who prefer not to take a daily dose. Many formulations combine buprenorphine with naloxone, an added ingredient that discourages misuse.
Methadone also activates opioid receptors but more fully than buprenorphine. It’s taken as an oral liquid or tablet, typically dispensed daily at specialized clinics. Methadone has the longest track record of any MAT medication and tends to have slightly higher retention rates. After 12 months, roughly 57% of people in methadone programs remain in treatment, compared to about 48% in buprenorphine programs.
Naltrexone takes the opposite approach. Instead of activating opioid receptors, it blocks them entirely. If someone on naltrexone uses opioids, they won’t feel the effects. It’s available as a monthly injection. Because it blocks rather than activates receptors, a person needs to be fully detoxed from opioids before starting it, or they risk severe withdrawal symptoms.
Medications for Alcohol Use Disorder
Three FDA-approved medications also target alcohol addiction, each through a different mechanism.
Naltrexone works for alcohol the same way it works for opioids: by blocking receptors involved in the pleasurable sensations of drinking. Over time, this can reduce cravings and make drinking feel less rewarding. It’s available as a daily pill or a monthly injection.
Acamprosate helps people who have already stopped drinking stay sober by calming the brain’s hyperexcitable state during withdrawal and early recovery. When someone drinks heavily for a long time, their brain adapts to the presence of alcohol. Removing alcohol throws the brain into overdrive, producing anxiety, restlessness, and intense cravings. Acamprosate dampens that overactivity.
Disulfiram was the first drug approved to treat alcoholism, back in 1949, and it works through deterrence. It interferes with how your body breaks down alcohol, causing a buildup of a toxic byproduct that triggers nausea, skin flushing, and other unpleasant reactions if you drink. The anticipation of feeling sick is what helps some people avoid alcohol while taking it.
The Counseling Side of Treatment
Medication handles the physical component of addiction, but counseling and behavioral therapy address everything else: the thought patterns, emotional triggers, relationship problems, and life circumstances that fuel substance use. According to federal guidelines, psychosocial interventions serve three main roles in MAT. They keep patients engaged in treatment, help them change behaviors, and treat co-occurring mental health conditions like depression or anxiety that often accompany addiction.
Several evidence-based therapies are commonly used. Cognitive behavioral therapy (CBT) helps people identify the situations, thoughts, and emotions that trigger cravings, then develop strategies to manage them. It focuses on recognizing high-risk scenarios before they lead to relapse. Motivational enhancement therapy uses interviewing techniques to strengthen a person’s own motivation to change, rather than imposing external pressure. The community reinforcement approach takes a broader view, working to build a supportive environment through employment assistance, relationship counseling, and social skills training so that a person’s daily life reinforces recovery rather than undermining it.
Contingency management is another approach that rewards patients for meeting goals, like clean drug tests or consistent attendance. Peer support services, family therapy, and even phone-based interventions round out the options. Most treatment programs use some combination of these rather than relying on a single method.
How Long Treatment Lasts
There’s no standard timeline for MAT. Treatment length varies from months to years depending on the individual. Long-term treatment is often necessary to prevent relapse, and clinical guidelines emphasize that removing someone from medication abruptly or prematurely increases the risk of relapse and overdose.
When the time comes to taper off medication, the decision depends on several factors: how well the person is tolerating the medication, whether they’re experiencing side effects, and how much progress they’ve made in their recovery. Tapering itself typically takes several months and is done gradually under medical supervision. Some people stay on medication indefinitely, and that’s considered a valid and effective treatment path, not a failure.
How Well MAT Works
A successful MAT program is generally benchmarked at keeping at least 50% of participants in treatment after 12 months. Across studies, the average 12-month retention rate is about 54%, which means more than half of people who start treatment are still engaged a year later. At three months, retention rates are considerably higher, around 75% for buprenorphine and 78% for methadone.
Retention matters because time in treatment correlates directly with better outcomes. Twelve months of program participation is associated with significant reductions in heroin use and crime. One program reported that 84% of participants were abstinent from opioids at the one-year mark, with 62% abstinent from all illicit substances. With prolonged treatment, many people are able to stop illicit drug use permanently.
MAT also plays a critical role in overdose prevention. By stabilizing people on regulated medications rather than leaving them to cycle through withdrawal, relapse, and increasingly dangerous use, it dramatically lowers the risk of fatal overdose.
Getting Access to MAT
Access to MAT, particularly buprenorphine, has expanded significantly in recent years. In 2023, Congress eliminated the special waiver (known as the X-waiver) that previously limited which doctors could prescribe buprenorphine and capped how many patients they could treat. Now, any practitioner with a DEA registration and authority to prescribe schedule III controlled substances can prescribe buprenorphine without additional certification or patient limits.
Telehealth access has also broadened. As of a 2025 federal rule, practitioners can prescribe an initial six-month supply of buprenorphine through a telemedicine visit, including audio-only phone calls. After that initial period, follow-up evaluations can continue via telemedicine or in person. The prescribing practitioner reviews the state prescription drug monitoring database and the pharmacist verifies the patient’s identity before filling the prescription. These changes have made it possible for people in rural areas or without easy access to specialized clinics to begin treatment from home.
Methadone remains more restricted. It’s typically dispensed through certified opioid treatment programs rather than by a regular doctor’s office, which can limit access for some people. Naltrexone, on the other hand, can be prescribed by any healthcare provider and doesn’t require any special authorization.